| Name | Title | Contact Details |
|---|
Our revolutionary technology is radically different than any other form of automated medical billing software or revenue cycle management. Unlike a PMS vendor or a clearinghouse, the Encoda BackOffice suite of products enhances and improves existing billing systems and billing service providers’ operations, making them more intelligent. The difference? On average, our customers increase staff productivity by more than 30% and dramatically reduce operating expenses, helping their practices to grow. How do we do this? We apply business intelligence and programming logic tools from the high-tech community to healthcare, and pass those technological advantages on to medical business offices. In adding this advanced technology to our clients’ systems, we create a direct connection between clients and payers, seamlessly integrating the two environments eliminating the need for human intervention.
With more than 51 programs across the U.S. and abroad, RI specializes in Crisis, Health, Recovery and Consulting Services. RI Crisis is rapidly expanding while enhancing technologies and service lines within our existing array of RRC`s(Crisis Stabilization Programs), E&Ts (Involuntary & Court-ordered Treatment), and Crisis Respites.
Dinatec is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chambers of Commerce Service Corporation is a Wexford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.